Browse drugs

…onclusions This hypothesis-generating study suggests that early belimumab use may rapidly delay damage in SLE. Future research is needed …

…l. Seven patients discontinued belimumab.Conclusion Progressive belimumab dose spacing and withdrawal, coupled with clinical monitoring, …

… in leucopenia were slower, with no apparent difference between belimumab and placebo.Conclusion This post hoc analysis of data from five…

…l (66.7%), azathioprine (11%) and tacrolimus (11%)]. 2 received Belimumab monotherapy.Baseline combined SLEDAI was 10.2±3.9 (range 4-16),…

…ndings suggest potential renal protective effects through which belimumab may prevent progression to LN.Funding: GSKOriginal presentation…

…teristics of SLE patientsConclusions In this real-world cohort, belimumab treatment was associated with significant improvements in disea…

…mean current age of 45.3 years. Biologic therapies consisted of Belimumab in 47 patients (56.0%), Anifrolumab in 26 (31.0%), and Rituxima…

…Objectives Both telitacicept and belimumab are approved for treating active systemic lupus erythematosus (…

… White subgroups exhibited significantly higher attainment with belimumab versus placebo.Conclusion Belimumab was associated with higher …

…ods A retrospective analysis included SLE patients treated with belimumab (n=25), obinutuzumab (n=8), and voclosporin (n=3) for >=6 month…

…ower levels of disease activity supports benefits of initiating belimumab treatment earlier in the disease course. Funding: GSK, Original…

…addition of two immunosuppressive therapies, anchored on either belimumab or voclosporin.3 4 Glucocorticoids should be administered initi…